![](/img/cover-not-exists.png)
Cost-Effectiveness of Pembrolizumab vs. Docetaxel for Treatment of Previously Treated PD-l1 Positive Advanced NSCLC Patients
Huang, M, Lou, Y, Pellissier, J, Burke, T, Liu, FX, Xu, R, Velcheti,Volume:
19
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2016.09.2233
Date:
November, 2016
File:
PDF, 71 KB
english, 2016